ChREBP promotes the differentiation of leukemia-initiating cells to inhibit leukemogenesis through the TXNIP/RUNX1 pathways
暂无分享,去创建一个
X. Tong | Junke Zheng | Chiqi Chen | Li Xie | Zhuo Yu | Hao Gu | Xiaoye Liu | Feifei Zhang | Fangzhen Xia | Jiangbo Wang | Hongxiang Zeng | Minle Li
[1] Howard Y. Chang,et al. Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation. , 2015, Cell stem cell.
[2] R. Chapple,et al. AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow. , 2015, Cell stem cell.
[3] R. Deberardinis,et al. Hypoxic metabolism in human hematopoietic stem cells , 2015, Cell & Bioscience.
[4] William J. Israelsen,et al. Cell-State-Specific Metabolic Dependency in Hematopoiesis and Leukemogenesis , 2014, Cell.
[5] A. Harris,et al. Role of carbohydrate response element-binding protein (ChREBP) in generating an aerobic metabolic phenotype and in breast cancer progression , 2013, British Journal of Cancer.
[6] N. Speck,et al. Distinct temporal requirements for Runx1 in hematopoietic progenitors and stem cells , 2013, Development.
[7] Masahiro Nakagawa,et al. Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. , 2013, The Journal of clinical investigation.
[8] N. Speck,et al. Gata2 is required for HSC generation and survival , 2013, The Journal of experimental medicine.
[9] John M. Ashton,et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. , 2013, Cell stem cell.
[10] J. D. Engel,et al. Conditional Gata2 inactivation results in HSC loss and lymphatic mispatterning. , 2012, The Journal of clinical investigation.
[11] S. Sugano,et al. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. , 2012, Blood.
[12] A. F. Stewart,et al. ChREBP Mediates Glucose-Stimulated Pancreatic β-Cell Proliferation , 2012, Diabetes.
[13] H. Hock. A complex Polycomb issue: the two faces of EZH2 in cancer. , 2012, Genes & development.
[14] E. Ward,et al. Inhibitory receptors bind Angptls and support blood stem cells and leukemia development , 2012, Nature.
[15] Sung‐Min Ahn,et al. Integrated Expression Profiling and Genome-Wide Analysis of ChREBP Targets Reveals the Dual Role for ChREBP in Glucose-Regulated Gene Expression , 2011, PloS one.
[16] Yang Liu,et al. Targeting HIF1α eliminates cancer stem cells in hematological malignancies. , 2011, Cell stem cell.
[17] T. Mak,et al. Regulation of cancer cell metabolism , 2011, Nature Reviews Cancer.
[18] Qiang Yu,et al. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. , 2010, Blood.
[19] Cheng Cheng Zhang,et al. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. , 2010, Cell stem cell.
[20] O. Abdel-Wahab,et al. Metabolism and the leukemic stem cell , 2010, The Journal of experimental medicine.
[21] C. Thompson,et al. The glucose-responsive transcription factor ChREBP contributes to glucose-dependent anabolic synthesis and cell proliferation , 2009, Proceedings of the National Academy of Sciences.
[22] Ken Chen,et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.
[23] J. Hsieh,et al. MLL fusions: Pathways to leukemia , 2009, Cancer biology & therapy.
[24] L. Cantley,et al. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.
[25] D. Ayer,et al. Glucose sensing by MondoA:Mlx complexes: A role for hexokinases and direct regulation of thioredoxin-interacting protein expression , 2008, Proceedings of the National Academy of Sciences.
[26] J. Chung,et al. Diverse functions of VDUP1 in cell proliferation, differentiation, and diseases. , 2007, Cellular & molecular immunology.
[27] J. Girard,et al. ChREBP, a transcriptional regulator of glucose and lipid metabolism. , 2007, Annual review of nutrition.
[28] D. Muoio. TXNIP links redox circuitry to glucose control. , 2007, Cell metabolism.
[29] S. Forman,et al. Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. , 2007, Cancer research.
[30] N. Sharpless,et al. ROS as a tumour suppressor? , 2006, Nature Cell Biology.
[31] T. Golub,et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9 , 2006, Nature.
[32] H. Aburatani,et al. Hepatocellular carcinoma in Txnip-deficient mice , 2006, Oncogene.
[33] E. Giannoni,et al. Intracellular Reactive Oxygen Species Activate Src Tyrosine Kinase during Cell Adhesion and Anchorage-Dependent Cell Growth , 2005, Molecular and Cellular Biology.
[34] H. Masutani,et al. Two distinct mechanisms for loss of thioredoxin-binding protein-2 in oxidative stress-induced renal carcinogenesis , 2005, Laboratory Investigation.
[35] H. Towle,et al. Direct Role of ChREBP·Mlx in Regulating Hepatic Glucose-responsive Genes* , 2005, Journal of Biological Chemistry.
[36] K. Song,et al. VDUP1 is required for the development of natural killer cells. , 2005, Immunity.
[37] M. Magnuson,et al. Hepatic Glucokinase Is Required for the Synergistic Action of ChREBP and SREBP-1c on Glycolytic and Lipogenic Gene Expression* , 2004, Journal of Biological Chemistry.
[38] Y. Ishii,et al. Loss of Thioredoxin-Binding Protein-2/Vitamin D3 Up-Regulated Protein 1 in Human T-Cell Leukemia Virus Type I-Dependent T-Cell Transformation , 2004, Cancer Research.
[39] C. Wollheim,et al. ChREBP Rather than USF2 Regulates Glucose Stimulation of Endogenous L-pyruvate Kinase Expression in Insulin-secreting Cells* , 2002, The Journal of Biological Chemistry.
[40] H. Yamashita,et al. Mechanism for Fatty Acid “Sparing” Effect on Glucose-induced Transcription , 2002, The Journal of Biological Chemistry.
[41] M. Sakurai,et al. A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[42] A Ballabio,et al. WBSCR14, a gene mapping to the Williams--Beuren syndrome deleted region, is a new member of the Mlx transcription factor network. , 2001, Human molecular genetics.
[43] T. Tang,et al. Human glucose‐6‐phosphate dehydrogenase (G6PD) gene transforms NIH 3T3 cells and induces tumors in nude mice , 2000, International journal of cancer.
[44] M. Matsui,et al. Identification of Thioredoxin-binding Protein-2/Vitamin D3 Up-regulated Protein 1 as a Negative Regulator of Thioredoxin Function and Expression* , 1999, The Journal of Biological Chemistry.
[45] S. Baer,et al. Expression of the human erythrocyte glucose transporter Glut1 in cutaneous neoplasia. , 1997, Journal of the American Academy of Dermatology.
[46] M. Copland,et al. EZH2 in normal and malignant hematopoiesis , 2014, Leukemia.
[47] R. Arceci. PML targeting eradicates quiescent leukaemia-initiating cells , 2009 .
[48] H. S. Jung,et al. Optimized THP-1 differentiation is required for the detection of responses to weak stimuli , 2007, Inflammation Research.
[49] D. Ayer,et al. The Mlx network: evidence for a parallel Max-like transcriptional network that regulates energy metabolism. , 2006, Current topics in microbiology and immunology.